drugset
drugset / Trial / NCT04591301

The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects

NCT04591301 ↗

Phase 1 Completed 69 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Male and Female Subjects

Timeline

Start
2019-07-04
Primary completion
2019-12-06
Completion
2019-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC113995PA•H2O Unknown 2.5 mg Oral
Subject HEC113995PA•H2O Unknown 5 mg Oral
Subject HEC113995PA•H2O Unknown 10 mg Oral
Subject HEC113995PA•H2O Unknown 20 mg Oral
Subject HEC113995PA•H2O Unknown 40 mg Oral
Subject HEC113995PA•H2O Unknown 60 mg Oral
Subject HEC113995PA•H2O Unknown 80 mg Oral

Indications

major depressive disorder